Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
F. Wang, K. Morita, C. DiNardo, K. Furudate, T. Tanaka, Y. Yan, K. Patel, K. MacBeth, B. Wu, G. Liu, M. Frattini, J. Matthews, L. Little, C. Gumbs, X. Song, , K. Takahashi
The paper identifies leukemia stemness and co-occurring mutations as drivers of resistance to IDH inhibitors in AML through genomic analyses of treated patients.
bioRxiv · Oct 27, 2020Cancer Biology